Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Abstract
Combined targeting of CDK4/6 and ER is now the standard of care for patients with advanced ER+/HER2− breast cancer. However, acquired resistance to these therapies frequently leads to disease progression. As such, it is critical to identify the mechanisms by which resistance to CDK4/6-based therapies is acquired and also identify therapeutic strategies to overcome resistance.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 14, 2020
- Source ID
- 10.1186/s13058-020-01320-8
Entities
People
- Alex Gaither
- Dennis J. Slamon
- Dylan Conklin
- Emmanuelle Ditomaso
- Faye Su
- Kevin Chau
- Kristine Rose
- Martina S. J. Mcdermott
- Naveen Babbar
- Neil A O'Brien
- Raul Ayala
- Ronald Linnartz
- Samit Hirawat
- Sara A. Hurvitz
- Suruchi Salgar
- Tong Luo
Organizations
- Chiron Corporation